慢性肾病患者NT-proBNP心衰风险预测的肾功能特异性阈值研究
结果显示eGFR特异性阈值使心衰风险预测的NRI在1至5期CKD中提升19%至55%,而统一阈值125 pg/mL对5期CKD患者无额外预测价值。
要点
- CKD患者NT-proBNP升高常见,统一阈值125 pg/mL不适用于全肾功能谱。
- 按eGFR分层设定NT-proBNP阈值可显著改善心衰风险分层。
- 5期CKD(eGFR<15 mL/min/1.73 m²)患者使用统一阈值无预测价值。
核心结论
- CKD患者NT-proBNP水平需结合肾功能解读,eGFR特异性阈值优于统一阈值。
- 研究支持采用肾功能调整的NT-proBNP阈值以改善心衰风险预测。
研究设计与样本
- 回顾性多中心观察性队列研究,数据来自中国肾脏数据系统。
- 按eGFR分类建立NT-proBNP肾功能特异性阈值,用多变量Cox比例风险模型评估心衰风险。
- 用净重分类改善(NRI)比较特异性阈值与统一阈值125 pg/mL的预测价值。
主要发现
- 使用统一阈值时67%患者NT-proBNP升高,使用eGFR特异性阈值时为23%。
- 最佳NT-proBNP阈值随肾功能下降而升高,5期CKD(eGFR<15 mL/min/1.73 m²)时最高。
- eGFR特异性阈值使1至5期CKD的心衰风险预测NRI提升19%至55%。
- 统一阈值对5期CKD患者无额外预测价值。
关键数值与推荐
- 统一阈值125 pg/mL用于比较。
- eGFR特异性阈值按CKD分期建立,5期CKD阈值最高。
- NRI提升范围19%至55%(1至5期CKD)。
- 5期CKD定义为eGFR<15 mL/min/1.73 m²。
临床怎么用
- 临床解读CKD患者NT-proBNP时应结合eGFR分期,避免使用统一阈值。
- 对5期CKD患者,统一阈值125 pg/mL不应作为心衰风险判断依据。
- 采用肾功能特异性阈值可改善心衰风险分层,辅助临床决策。
局限性
- 回顾性队列设计可能存在残余混杂。
- 研究基于中国肾脏数据系统人群,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels are common in patients with chronic kidney disease (CKD), but uniform thresholds derived from the general population may not accurately predict heart failure (HF) risk across stages of kidney function. This study aimed to determine whether thresholds specific to kidney function categories improve HF risk prediction in CKD. METHODS: This retrospective cohort study used data from the China Renal Data System, including 18 261 patients with CKD without prior HF. Kidney function-specific thresholds for NT-proBNP were established based on estimated glomerular filtration rate (eGFR) categories, and associations with HF risk were assessed using multivariable Cox proportional hazard models. The predictive value of these thresholds was compared with a uniform threshold of 125 pg/mL using Net Reclassification Improvement (NRI). RESULTS: Elevated NT-proBNP was observed in 67% of patients using the uniform threshold compared with 23% when using eGFR-specific thresholds. Optimal NT-proBNP thresholds increased with declining kidney function, reaching the highest level in stage 5 CKD (eGFR <15 mL/min/1.73 m²). eGFR-specific thresholds significantly improved HF risk prediction, with NRI gains of 19% to 55% across stages 1 to 5, while the uniform threshold added no predictive value for patients with stage 5 CKD. CONCLUSIONS: In patients with CKD, NT-proBNP levels must be interpreted in the context of kidney function, as eGFR-specific thresholds provide superior HF risk stratification. These findings support adopting kidney function-adjusted thresholds rather than a uniform cut-off to improve HF risk prediction.
引用
- Lu, Chen, Chen, et al. Determining kidney function-specific thresholds for N-terminal pro-B-type natriuretic peptide in heart failure risk prediction among patients with chronic kidney disease: a multicentre, observational, cohort study. Heart. 2025. PMID: 40010937. doi:10.1136/heartjnl-2024-324679
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。